Drug General Information (ID: DDIBQEIK18)
Drug Name			Rituximab		Drug Info		Fingolimod		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Selective Immunosuppressants

Mechanism of Rituximab-Fingolimod Interaction (Severity Level: Major)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Rituximab				Fingolimod
Mechanism		Immunosuppressive effects				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Rituximab and Fingolimod

Recommended Action
Management		The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.

References
1	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.